BACKGROUND: Pathological complete response (pCR) after neoadjuvant chemotherapy (NCT) in breast cancer (BC) identifies patients with good prognosis. AIM: To assess if the clinico-pathological subtype, determined by classic immunohistochemical (IHC) markers, is able to predict pCR and prognosis in BC patients treated with NCT. MATERIAL AND METHODS: One hundred thirty three BC patients aged 24-80 years, were treated with NCT. Clinico-pathological subtype was defined based on classic IHC markers. pCR was defined as the absence of invasive neoplastic cells in the breast and lymph nodes, on final breast surgery. RESULTS: pCR was achieved in 8.2% of patients, 3.5 and 19.5% in luminal and hormonal receptor (HR) negative tumors respectively (p < 0.01). Median follow-up was 72.6 months (3.5-190). Patients who achieved pCR had higher overall survival (OS) (p = 0.04). A univariate analysis revealed that size of the tumor, ratio of metastatic to examined lymph nodes and absence of HR were significant predictors of pCR. These findings were not replicated in the multivariate analyses. CONCLUSIONS: Clinico-pathological subtypes were independent prognostic factors for pCR and OS in BC patients in our cohort. These findings support using classic and cheap biomarkers as a predictive tool for NCT in BC.
BACKGROUND: Pathological complete response (pCR) after neoadjuvant chemotherapy (NCT) in breast cancer (BC) identifies patients with good prognosis. AIM: To assess if the clinico-pathological subtype, determined by classic immunohistochemical (IHC) markers, is able to predict pCR and prognosis in BC patients treated with NCT. MATERIAL AND METHODS: One hundred thirty three BC patients aged 24-80 years, were treated with NCT. Clinico-pathological subtype was defined based on classic IHC markers. pCR was defined as the absence of invasive neoplastic cells in the breast and lymph nodes, on final breast surgery. RESULTS: pCR was achieved in 8.2% of patients, 3.5 and 19.5% in luminal and hormonal receptor (HR) negative tumors respectively (p < 0.01). Median follow-up was 72.6 months (3.5-190). Patients who achieved pCR had higher overall survival (OS) (p = 0.04). A univariate analysis revealed that size of the tumor, ratio of metastatic to examined lymph nodes and absence of HR were significant predictors of pCR. These findings were not replicated in the multivariate analyses. CONCLUSIONS: Clinico-pathological subtypes were independent prognostic factors for pCR and OS in BC patients in our cohort. These findings support using classic and cheap biomarkers as a predictive tool for NCT in BC.
Authors: Mauricio Rivas; Francisco Acevedo; Francisco Dominguez; Hector Galindo; Mauricio Camus; David Oddo; Alejandra Villarroel; Dravna Razmilic; Jose Peña; Matias Munoz Medel; Maria Elena Navarro; Alejandra Perez-Sepulveda; Lidia Medina; Tomas Merino; Juan Briones; Alexis Kalergis; Cesar Sanchez Journal: Asian Pac J Cancer Prev Date: 2019-07-01
Authors: Cristóbal Maiz; Fernando Silva; Francisco Domínguez; Héctor Galindo; Mauricio Camus; Augusto León; David Oddó; Alejandra Villarroel; Dravna Razmilic; María Elena Navarro; Lidia Medina; Tomás Merino; Eugenio Vines; José Peña; Daniela Maldonado; Mauricio P Pinto; Francisco Acevedo; César Sánchez Journal: Ecancermedicalscience Date: 2020-01-23
Authors: Javier Valdés-Ferrada; Natalia Muñoz-Durango; Alejandra Pérez-Sepulveda; Sabrina Muñiz; Irenice Coronado-Arrázola; Francisco Acevedo; Jorge A Soto; Susan M Bueno; Cesar Sánchez; Alexis M Kalergis Journal: Front Immunol Date: 2020-07-09 Impact factor: 7.561